The side effects were similar in both groups, with the most common issues being neutropenia, arthralgia and liver-related events. "Overall, the NATALEE trial supports support ribociclib plus endocrine ...

The drug, also known as ribociclib, has been approved for use ... with Kisqali medicine are low white blood cell count or ...

At the European Society for Medical Oncology (ESMO) Congress this week, investigators presented data for a new and potentially important drug, ribociclib (Novartis). This oral medication is ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.

Ribociclib in combination with an aromatose inhibitor for previously untreated advanced or metastatic hormone receptor-positive, her2-negative breast cancer. The NICE appraisal committee wanted to ...

Ribociclib – a drug already used to treat breast cancer – may help slow the growth of diffuse hemispheric glioma (DHG), new research has found. Diffuse hemispheric glioma is a rare, high-grade ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an alternative to multi-drug neoadjuvant chemotherapy. The trial involved high risk ...

Already approved in the US since last year, Verzenio will compete with Pfizer’s Ibrance (palbociclib), and Novartis’ Kisqali (ribociclib), which are in the same class of drugs, which work by ...